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A bs tr ac t
Background
A recent meta-analysis raised concern regarding an increased risk of myocardial in-
farction and death from cardiovascular causes associated with rosiglitazone treatment 
of type 2 diabetes.
Methods
We conducted an unplanned interim analysis of a randomized, multicenter, open-label, 
noninferiority trial involving 4447 patients with type 2 diabetes who had inadequate 
glycemic control while receiving metformin or sulfonylurea, in which 2220 patients 
were assigned to receive add-on rosiglitazone (rosiglitazone group), and 2227 to receive 
a combination of metformin plus sulfonylurea (control group). The primary end point 
was hospitalization or death from cardiovascular causes.
Results
Because the mean follow-up was only 3.75 years, our interim analysis had limited sta-
tistical power to detect treatment differences. A total of 217 patients in the rosiglitazone 
group and 202 patients in the control group had the adjudicated primary end point 
(hazard ratio, 1.08; 95% confidence interval [CI], 0.89 to 1.31). After the inclusion 
of end points pending adjudication, the hazard ratio was 1.11 (95% CI, 0.93 to 1.32). 
There were no statistically significant differences between the rosiglitazone group 
and the control group regarding myocardial infarction and death from cardiovascular 
causes or any cause. There were more patients with heart failure in the rosiglitazone 
group than in the control group (hazard ratio, 2.15; 95% CI, 1.30 to 3.57).
Conclusions
Our interim findings from this ongoing study were inconclusive regarding the effect 
of rosiglitazone on the overall risk of hospitalization or death from cardiovascular 
causes. There was no evidence of any increase in death from either cardiovascular 
causes or all causes. Rosiglitazone was associated with an increased risk of heart 
failure. The data were insufficient to determine whether the drug was associated 
with an increase in the risk of myocardial infarction. (ClinicalTrials.gov number, 
NCT00379769.)
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For patients with type 2 diabetes, car-diovascular disease is the leading cause of death and the major cause of morbidity.1 In 
such patients, cardiovascular risk is considerably 
elevated,2 although recent reports have moderat-
ed this concern.3,4 Factors that are implicated in 
the development of atherosclerosis include dyslip-
idemia, obesity, hypertension, hyperglycemia, and 
hyperinsulinemia.5
Type 2 diabetes is a progressive disease and its 
prevalence in the population is increasing. Since 
there is greater attention to glycemic targets, more 
patients are receiving combination therapies. Clin-
ical trials comparing monotherapies are common, 
but comparisons of new dual-agent combinations 
with the standard of metformin plus sulfonylurea 
are rare. The Rosiglitazone Evaluated for Cardiac 
Outcomes and Regulation of Glycaemia in Diabe-
tes (RECORD) trial is a long-term, multicenter, 
randomized, open-label study6 that compares car-
diovascular outcomes in patients with type 2 dia-
betes treated with rosiglitazone (Avandia) plus 
metformin or sulfonylurea (rosiglitazone group) 
with outcomes in patients treated with metformin 
plus sulfonylurea (control group). The results of 
the United Kingdom Prospective Diabetes Study 
(UKPDS) suggest that the comparators metformin 
and sulfonylurea used in the RECORD trial reduce 
myocardial infarction by 39% and 16%, respec-
tively, as compared with conventional treatment 
and diet.7,8
After a recent meta-analysis by Nissen and 
Wolski9 raised concern about the cardiovascular 
safety of rosiglitazone, the current totality of evi-
dence needs to be made available. Accordingly, this 
interim report presents the outcomes and deaths 
from cardiovascular causes so far in the RECORD 
study.
Me thods
Patients
The RECORD study has been described in detail 
previously.6 We recruited patients for the study 
from April 2001 through April 2003. Eligible pa-
tients had type 2 diabetes, as defined by criteria of 
the World Health Organization10; were between 
the ages of 40 and 75 years; had a body-mass in-
dex (the weight in kilograms divided by the square 
of the height in meters) of more than 25.0; and 
had a glycated hemoglobin level of more than 7.0% 
and less than or equal to 9.0% while receiving max-
imum doses of metformin or a sulfonylurea. Ex-
clusion criteria were the current use of other glu-
cose-lowering agents, hospitalization for a major 
cardiovascular event in the previous 3 months, 
a planned cardiovascular intervention, heart fail-
ure, clinically significant hepatic disease, renal 
impairment, and uncontrolled hypertension. The 
study protocol was approved by ethics review com-
mittees or institutional review boards in accor-
dance with the laws and customs of each country 
participating in the study.6 Written informed con-
sent was obtained from all patients. 
Study Design
The study is being conducted at 338 centers in 23 
countries in Europe and Australasia. After a 4-week 
run-in period, patients who were already taking 
a sulfonylurea were randomly assigned to receive 
either additional rosiglitazone or metformin; those 
taking metformin were assigned to receive either 
additional rosiglitazone or a sulfonylurea (glybur-
ide, gliclazide, or glimepiride, according to local 
practice). Random allocation was performed by 
telephone, with random permuted blocks stratified 
according to background medication.
Throughout the study, the target glycated he-
moglobin level was 7.0% or less. The starting dose 
of rosiglitazone (Avandia, GlaxoSmithKline) was 
4 mg per day. The starting doses of metformin and 
sulfonylurea were determined according to local 
practice. If the glycated hemoglobin level exceeded 
7.0% after 8 weeks of treatment, the doses of study 
drugs were increased to a maximum daily dose of 
8 mg of rosiglitazone, 2550 mg of metformin, 
15 mg of glyburide, 240 mg of gliclazide, and 4 mg 
of glimepiride. If the glycated hemoglobin level 
exceeded 8.5% while patients were receiving the 
maximum tolerated dose, a third agent was added 
for patients in the rosiglitazone group or insulin 
was initiated for patients in the control group. If 
patients receiving triple therapy in the rosiglit-
azone group had glycated hemoglobin levels of 
more than 8.5%, the study protocol recommended 
that rosiglitazone be stopped and insulin therapy 
started.
Outcome Measures
The primary end point was hospitalization (for 
acute myocardial infarction, congestive heart fail-
ure, stroke, unstable angina pectoris, transient 
ischemic attack, unplanned cardiovascular revas-
cularization, amputation of extremities, or any 
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other definite cardiovascular reason) or death from 
cardiovascular causes (including heart failure, acute 
myocardial infarction, sudden death, and death 
caused by acute vascular events including stroke); 
the outcome was analyzed as the time to first oc-
currence. Members of an independent committee 
evaluating clinical end points (five cardiologists, 
a neurologist, and a diabetologist) were unaware 
of study-group assignments and used prespecified 
criteria to adjudicate all potential outcomes report-
ed by investigators. Evaluators in the trial’s contract 
organization (Quintiles) were unaware of study-
group assignments in screening all serious adverse 
events for potential end points.
This interim report evaluated data that were 
available as of March 30, 2007. Secondary end 
points were death from cardiovascular causes and 
from any cause, myocardial infarction (resulting in 
either hospitalization or death), congestive heart 
failure (hospitalization or death), and the compos-
ite of death from cardiovascular causes, myocar-
dial infarction, and stroke. Some events were 
pending adjudication while this report was being 
written. Analyses are reported both for adjudicated 
events only and for adjudicated events plus events 
pending adjudication. For 19 cardiovascular deaths 
pending adjudication, we cannot determine yet 
whether any were due to acute myocardial infarc-
tion or congestive heart failure.
Study Oversight
An independent data and safety monitoring board 
meets twice annually to review unblinded safety 
data for the ongoing study; the most recent meet-
ing took place on May 24, 2007. Members of the 
steering committee (seven academic investigators 
and one representative of the sponsor) developed 
the study design, had full access to the interim 
data, were responsible for the decision to publish 
the results, and wrote the manuscript. The com-
mittee members vouch for the accuracy and com-
pleteness of the data reported. Study committees 
and investigators are listed in the Appendix.
Statistical Analysis 
The RECORD study was designed as a noninferi-
ority trial. The rosiglitazone group was defined as 
noninferior to the control group if the upper limit 
of the two-sided 95% confidence interval for the 
hazard ratio for the primary end point comparing 
the rosiglitazone group with the control group was 
below 1.20 on completion of the study. A total of 
4000 patients to be followed for a median of 6 years 
would give a power of 99% to detect such nonin-
feriority when the control group had an event rate 
of 11% per year (3% with deaths from cardiovas-
cular causes and 8% with hospitalizations), allow-
ing for a 2% annual loss to follow-up.
This interim report follows a prespecified plan 
for statistical analysis. All analyses were performed 
according to the intention-to-treat principle, with 
the exclusion of 11 patients who received no study 
medication. The time from randomization to the 
event was derived for each end point, with follow-
up censored at the cutoff date of March 30, 2007, 
for patients who did not have an event. Cumula-
tive incidence was estimated with the use of the 
Kaplan–Meier method. The relative risk comparing 
the rosiglitazone group with the control group was 
estimated as a hazard ratio and 95% confidence 
interval on the basis of Cox proportional-hazards 
regression stratified according to background 
medication. Two-sided P values were calculated 
with the use of log-rank tests, unadjusted for mul-
tiple testing. 
R esult s
Patients
Of 7428 patients who underwent screening, 4458 
were randomly assigned to study groups (Fig. 1). 
No study medication was received by 11 patients 
(6 in the rosiglitazone group and 5 in the control 
group), who were excluded from the analysis. At 
baseline, 2222 patients who were receiving metfor-
min monotherapy were assigned to receive either 
rosiglitazone plus metformin (1117 patients) or 
metformin plus sulfonylurea (1105 patients); 2225 
patients receiving sulfonylurea monotherapy were 
assigned to receive rosiglitazone plus sulfonylurea 
(1103) or metformin plus sulfonylurea (1122). Re-
sults presented here are for all patients who were 
randomly assigned to receive rosiglitazone com-
binations (2220), as compared with all patients 
assigned to receive metformin plus sulfonylurea 
(2227).
Approximately 10% of patients (218 in the rosi-
glitazone group and 223 in the control group) were 
lost to follow-up. This fact, along with the much 
lower overall event rate than we had predicted, 
substantially lowered the statistical power of our 
analysis. A total of 140 patients in the rosigli-
tazone group and 244 patients in the control 
group began to receive insulin. At the latest visit, 
1626 patients in the rosiglitazone group and 1476 
patients in the control group were receiving their 
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allocated treatment. In total, 675 patients (263 
in the rosiglitazone group and 412 in the control 
group) withdrew from receiving study drugs but 
were still in follow-up.
Baseline characteristics were well balanced be-
tween the groups (Table 1). Table 2 shows by group 
the numbers of patients with the primary end 
point (hospitalization or death from cardiovascu-
lar causes) and several secondary end points over 
a mean follow-up of 3.75 years (3.77 years for the 
rosiglitazone group and 3.73 years for the control 
group). Results are reported for adjudicated events 
and for events adjudicated plus those pending ad-
judication. Kaplan–Meier plots are shown in Fig-
ures 2 and 3.
For adjudicated primary end points (217 in the 
rosiglitazone group and 202 in the control group), 
the hazard ratio was 1.08 (95% confidence inter-
val [CI], 0.89 to 1.31). An additional 91 patients 
(50 in the rosiglitazone group and 41 in the con-
trol group) had potential primary events reported 
by investigators, but these events were pending 
adjudication. The inclusion of these events resulted 
in a hazard ratio of 1.11 (95% CI, 0.93 to 1.32). 
A subgroup analysis of patients who were classi-
fied according to previous monotherapy with met-
formin or sulfonylurea revealed no evidence of a 
treatment-by-stratum interaction (interaction test, 
P = 0.41). The time-to-event curves in Figure 2 may 
suggest possible divergence between groups, with 
more events in the rosiglitazone group after 2.5 
years of follow-up. However, data after 4 years in-
volve small numbers of patients, and further fol-
low-up will be necessary.
There was no statistically significant difference 
between the rosiglitazone group and the control 
group for the following secondary end points: 
acute myocardial infarction, death from cardiovas-
cular causes or any cause, or the composite of 
cardiovascular death, myocardial infarction, and 
stroke (both for adjudicated events and adjudicated 
plus pending events). However, the power to detect 
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Figure 1. Enrollment and Outcomes.
The numbers of participants who were assessed for safety were 2220 in the rosiglitazone group and 2227 in the con-
trol group.
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significant differences was low, as reflected by the 
wide 95% confidence intervals (Table 2). The haz-
ard ratio for death from cardiovascular causes for 
adjudicated plus pending events was 0.80 (95% CI, 
0.52 to 1.24). For myocardial infarction, the hazard 
ratio for adjudicated plus pending events was 1.23 
(95% CI, 0.81 to 1.86).
Patients in the rosiglitazone group had a sig-
nificantly higher risk of congestive heart failure 
than did patients in the control group, with 38 
versus 17 adjudicated events (hazard ratio, 2.24; 
95% CI, 1.27 to 3.97). The inclusion of events 
pending adjudication increased the number of 
events to 47 and 22, respectively (hazard ratio, 
2.15; 95% CI, 1.30 to 3.57), resulting in an excess 
risk of heart failure in the rosiglitazone group of 
3.0 (95% CI, 1.0 to 5.0) per 1000 patient-years of 
follow-up.
Discussion
Since patients with type 2 diabetes have a high 
risk of cardiovascular disease, any hypoglycemic 
agent the patient receives should not worsen that 
risk and preferably should lower it. Although the 
RECORD study is ongoing, we believe the excep-
tional circumstances surrounding a recent safety 
concern regarding rosiglitazone make it impor-
tant to publish interim data.
A recent meta-analysis by Nissen and Wolski 
raised concern that rosiglitazone was associated 
with an increased risk of myocardial infarction 
and death from cardiovascular causes.9 The limi-
tations of the meta-analysis have been pointed out 
by its authors and by others.11 Many contributing 
studies were small-scale and short-term, were de-
signed to evaluate glycemic control, had no event 
adjudication, and had an imbalance in follow-up 
(with more patients in the control group with-
drawing owing to hyperglycemia). Trials with no 
myocardial infarctions and no deaths from car-
diovascular causes were excluded, and rates of 
myocardial infarction were low.12
The RECORD trial is a large, randomized, long-
term study involving patients with type 2 diabetes 
that was designed to assess the cardiovascular 
safety of rosiglitazone combined with metformin 
or sulfonylurea, as compared with the combina-
tion of metformin and sulfonylurea, medications 
with previous evidence of a reduction in cardiovas-
cular risk.7,8 All cardiovascular end points that are 
reported by investigators in the trial undergo in-
dependent blinded adjudication to enhance the 
quality of the data. A wide variety of patients with 
type 2 diabetes, with and without previous car-
diovascular disease, are included in the study.
This interim report is based on data for 4447 
participants with a mean follow-up of 3.75 years, 
representing 16,675 patient-years of follow-up — 
almost two thirds of the follow-up that was in-
Table 1. Baseline Characteristics of the Patients.*
Variable
Rosiglitazone Group 
(N = 2220)
Control Group 
(N = 2227)
Previous medication — no. (%)
Metformin only 1117 (50.3) 1105 (49.6)
Sulfonylurea only 1103 (49.7) 1122 (50.4)
Age — yr 58.4±8.3 58.5±8.3
Male sex — no. (%) 1142 (51.4) 1152 (51.7)
White race — no. (%)† 2200 (99.1) 2199 (98.7)
Time since diagnosis — yr 7.0±5.0 7.1±4.9
Body-mass index 31.6±4.7 31.5±4.9
Glycated hemoglobin — % 7.9±0.7 7.9±0.7
Fasting plasma glucose — mg/dl 177±43 177±40
Hypertension — no. (%)‡ 1754 (79.0) 1774 (79.7)
Ischemic heart disease — no. (%)
Any disease 359 (16.2) 374 (16.8)
Stable angina 222 (10.0) 228 (10.2)
Myocardial infarction 102 (4.6) 114 (5.1)
Unstable angina 20 (0.9) 30 (1.3)
Cerebrovascular disease — no. (%)
Any disease 100 (4.5) 97 (4.4)
Stroke 54 (2.4) 54 (2.4)
Transient ischemic attack 50 (2.3) 47 (2.1)
Peripheral arterial disease — no. (%) 124 (5.6) 131 (5.9)
Congestive heart failure — no. (%) 12 (0.5) 6 (0.3)
Lipid disorder — no. (%)§ 2123 (95.6) 2100 (94.3)
Smoking history — no. (%)
Current smoker 363 (16.4) 343 (15.4)
Former smoker 565 (25.5) 539 (24.2)
* Plus–minus values are means ±SD. The body-mass index is the weight in kilo-
grams divided by the square of the height in meters.
† Race was determined by the investigators.
‡ Hypertension was defined as a systolic blood pressure of more than 130 mm Hg 
or a diastolic blood pressure of more than 80 mm Hg.
§ A lipid disorder was defined by investigator-reported diagnosis or as a low-
density lipoprotein cholesterol level of 100 mg per deciliter or more, a triglyc-
eride level of 200 mg per deciliter or more, or a high-density lipoprotein cho-
lesterol level of less than 40 mg per deciliter for men or less than 50 mg per 
deciliter for women.
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tended by the end of the study. The study design 
calls for targeting similar glycemic control in the 
rosiglitazone group and the control group to as-
sess cardiovascular safety independent of glyce-
mia. Patients and investigators are encouraged to 
follow a carefully planned treatment algorithm. 
A recent report on the first 1122 patients showed 
that patients in the rosiglitazone group and the 
control group had similar glycemic control after 
18 months of treatment.13
Overall, the rate of primary end points (hospital-
ization or death from cardiovascular causes) was 
low: 3.1% per year for adjudicated plus pending 
events. The protocol excluded some high-risk pa-
tients (e.g., those with heart failure, hospitaliza-
tion for cardiovascular causes during the previous 
3 months, and pending cardiovascular interven-
tion). Targeting treatment toward current manage-
ment guidelines for dyslipidemia, hypertension, 
and improved glucose control may also contribute 
to the low event rate. The Fenofibrate Intervention 
and Event Lowering in Diabetes (FIELD, ISRCTN 
number 64783481) study reported an increase 
from 0 to 36% in the use of lipid-lowering thera-
py in its control group during 1998–2005.14 This 
finding reflects guidelines that patients should be 
actively treated to reduce cardiovascular risk, no-
tably with glucose-lowering drugs, statins, aspirin, 
and more intensive use of blood-pressure–lowering 
agents.15 Moreover, event rates in recent similar 
trials involving patients with diabetes — the Col-
laborative Atorvastatin Diabetes Study (CARDS,4 
NCT00327418), Heart Protection Study (HPS,3 
ISRCTN 48489393), and FIELD14 — are similar to 
those in the RECORD trial.
The interim results for the primary end point 
were inconclusive, with a hazard ratio of 1.08 
(95% CI, 0.89 to 1.31) on the basis of events ad-
Table 2. Hospitalization or Death from Cardiovascular Causes.* 
Variable
Rosiglitazone Group 
(N = 2220)
Control Group 
(N = 2227)
Hazard Ratio   
(95% CI) P Value
no. of patients
Adjudicated events
Primary end point 217 202 1.08 (0.89–1.31) 0.43
Death
From cardiovascular causes† 29 35 0.83 (0.51–1.36) 0.46
From any cause 74 80 0.93 (0.67–1.27) 0.63
Acute myocardial infarction‡ 43 37 1.16 (0.75–1.81) 0.50
Congestive heart failure‡ 38 17 2.24 (1.27–3.97) 0.006
Death from cardiovascular causes,  
myocardial infarction, and stroke
93 96 0.97 (0.73–1.29) 0.83
Events adjudicated and pending adjudication
Primary end point 267 243 1.11 (0.93–1.32) 0.26
Death
From cardiovascular causes† 37 46 0.80 (0.52–1.24) 0.32
Acute myocardial infarction‡ 49 40 1.23 (0.81–1.86) 0.34
Congestive heart failure‡ 47 22 2.15 (1.30–3.57) 0.003
Death from cardiovascular causes,  
myocardial infarction, and stroke
109 114 0.96 (0.74–1.24) 0.74
* Each patient was counted only once for each category. The primary end point was the first occurrence of a hospitaliza-
tion or death from cardiovascular causes. 
† Of the adjudicated deaths from cardiovascular causes, 38 (16 in the rosiglitazone group and 22 in the control group) 
were primary end points. The remainder occurred after the patient had already been hospitalized for a cardiovascular 
event. For deaths from cardiovascular causes that were adjudicated or pending adjudication, 47 (20 in the rosiglitazone 
group and 27 in the control group) were primary end points.
‡ This category included both hospitalizations and deaths. Some of the 19 deaths from cardiovascular causes (8 patients 
in the rosiglitazone group and 11 in the control group) that were pending adjudication may have been due to acute 
myocardial infarction or congestive heart failure, but these data were not available at the time of the study cutoff. 
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judicated by the committee reviewing clinical end 
points. In any interim trial report, there are inevi-
tably some potential primary events pending ad-
judication. Adding in these pending events in-
creased the hazard ratio to 1.11 (95% CI, 0.93 to 
1.32). Thus, the data for the primary end point are 
compatible with as much as a 7% improvement, 
or as much as a 32% worsening, in cardiovascular 
risk. The study lost statistical power because of 
the withdrawal of patients from their assigned 
treatment and losses to follow-up, although pa-
tients in the rosiglitazone group fared better in 
these respects than did patients in the control 
group. We cannot determine whether some con-
sequent bias in end-point ascertainment occurred. 
All serious adverse events were screened for pos-
sible end points.
The low rate of the primary end point, along 
with the notable loss to follow-up, meant that the 
study has less statistical power than was originally 
planned. Assuming a continued primary-event rate 
of 3.1% per year, we project that 750 patients will 
have a primary end point by study completion. 
Under the hypothesis of no true treatment differ-
ence, this estimate would provide a power of 70% 
to claim noninferiority relative to a noninferiority 
margin of 1.20 for the hazard ratio. However, we 
already have 510 patients with a primary event 
(adjudicated plus pending events) and an observed 
hazard ratio of 1.11, which means that the con-
ditional power to claim noninferiority on study 
completion is somewhat less.
As compared with the control group, the rosig-
litazone group had no evidence of an increased 
risk of death, either from any cause (hazard ratio, 
0.93; 95% CI, 0.67 to 1.27) or from cardiovascular 
causes (hazard ratio, 0.80, 95% CI, 0.52 to 1.24). 
The primary end point included all first hospital-
izations or deaths from cardiovascular causes and 
as such included myocardial infarction and con-
gestive heart failure. Our study showed that the 
risk of heart failure in the rosiglitazone group was 
more than twice that in the control group. This 
finding is consistent with previous evidence re-
garding heart failure and the thiazolidinedi-
ones.16,17 Although the absolute excess risk was 
relatively small, this finding is of concern and re-
inforces advice that patients should be warned of 
the risk and that thiazolidinediones should not 
be started or continued in patients with heart 
failure.
For acute myocardial infarction, the difference 
between the rosiglitazone group and the control 
group was not statistically significant (hazard ratio 
for adjudicated events, 1.16; 95% CI, 0.75 to 1.81; 
hazard ratio for adjudicated plus pending events, 
1.23; 95% CI, 0.81 to 1.86). These estimates are 
somewhat lower than those reported in the meta-
analysis by Nissen and Wolski.9 They are consis-
tent with as much as a 19% improvement, and as 
much as an 86% worsening, in risk. For the com-
posite end point of death from cardiovascular 
causes, myocardial infarction, and stroke, the rosig-
litazone group did not differ significantly from 
the control group.
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A significant limitation of our study was that 
it was an open-label trial. The allocation of drugs 
was nonblinded owing to the number of prepara-
tions and dosing schedules and because the time 
for the introduction of insulin therapy differed 
between groups. Monitoring staff checked site rec-
ords for missing events, and all serious adverse 
events underwent blinded screening for potential 
cardiovascular end points; in addition, the adju-
dication of events was blinded. These procedures 
and the choice of end points reduce, but do not 
remove, the risk of ascertainment bias.
The primary composite end point reflects the 
study objective — an assessment of overall car-
diovascular safety — but therefore includes some 
hospitalizations (e.g., for valvular disease) that 
no observer would consider potentially related to 
treatment. The inclusion of such events tends to 
favor the achievement of noninferiority. Hence, 
sensitivity analyses will be performed at the end of 
the study that include only events related to athero-
sclerotic arterial disease.
We made the decision to publish our interim 
findings because in their absence, concern raised 
by the meta-analysis by Nissen and Wolski could 
well compromise the study’s integrity through an 
increase in the dropout rate and potential biases 
in reporting events. At present, every effort is be-
ing made to maintain follow-up until study com-
pletion in 2 years. Extra inquiries to investigators, 
to identify any end points previously missed,18 are 
expected to reduce substantially the extent of loss 
to follow-up by the end of the study.
This interim analysis is restricted to a limited 
amount of information. The statistical plan was 
predefined. The intent was primarily to estimate 
treatment differences, with no planned action re-
garding study continuation, so the significance 
level of the final analysis was not affected. The 
final report will be more extensive, with data pre-
sented for different background medications and 
other subgroups and examining possible imbal-
ances across treatment groups for concomitant 
medications and other possible confounders.
In conclusion, our interim findings from a 
large, prospective trial are inconclusive with re-
spect to the primary end point of hospitalization 
or death from cardiovascular causes and are as 
yet insufficient to claim noninferiority. There is 
no evidence of any increased mortality, either from 
any cause or from cardiovascular causes. There is 
a significant increase in the risk of heart failure. 
The data do not allow a conclusion as to whether 
treatment with rosiglitazone results in a higher 
rate of myocardial infarction than does therapy 
with metformin or a sulfonylurea. The study’s data 
and safety monitoring board, which is charged 
with safeguarding the study patients, has recom-
mended continuation of the trial. Study comple-
tion will enable a clearer determination of the 
long-term cardiovascular effects of treatment with 
rosiglitazone and thus help determine the most 
appropriate combination therapies for patients 
with type 2 diabetes.
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